cyrilzakka/clinical-trials huggingface dataset:
Cognitive Remediation for Neuropsychological Impairment in Compulsive Hoarding

The primary aim of this pilot randomized controlled trial is to examine whether cognitive remediation, compared to a placebo, improves attention and related cognitive functions in patients with compulsive hoarding. The primary hypothesis is that compulsive hoarding patients who are treated with cognitive remediation will demonstrate improved cognitive skills at post-treatment compared to patients receiving placebo. This will be especially true of attention; memory and executive function skills may also be improved.

The primary aim of this pilot randomized controlled trial is to examine whether cognitive remediation, compared to a placebo, improves attention and related cognitive functions in patients with compulsive hoarding. Previous research has demonstrated that hoarders have diminished neuropsychological abilities, particularly in the areas of attention, memory, and executive function; and that cognitive remediation improves those functions in populations that are similarly impaired, such as in individuals with schizophrenia. The investigators will thus randomize 20 patients with compulsive hoarding to receive either cognitive remediation or a placebo condition. Before and after treatment, the investigators aim to assess the effects of cognitive remediation on neuropsychological functioning and hoarding severity. The primary specific aim is to examine whether cognitive remediation improves cognitive function in compulsive hoarders. The investigators hypothesize that compulsive hoarding patients who are treated with cognitive remediation will demonstrate improved cognitive skills at post-treatment compared to patients receiving placebo. This will be especially true of attention; memory and executive function skills may also be improved. A secondary, exploratory aim is to examine whether cognitive remediation improves hoarding severity, compared to placebo. The ultimate goal of this research is to determine the feasibility and appropriateness of pursuing larger-scale studies of the promising new approach of combining cognitive remediation with other treatments for compulsive hoarding-particularly cognitive-behavioral therapy (CBT).

Eligibility Criteria:
Inclusion Criteria:

* be over 18 years of age,
* have a current primary diagnosis of hoarding disorder
* have no untreated and/or unstable concurrent psychiatric diagnoses
* have a score on the ADHDSS that is one standard deviation or more above the mean
* have an Attentional Composite score on the computerized battery of neuropsychological tests (Doniger, 2010) that is one standard deviation or more below the mean
* be stable on all psychotropic medications during and up to four weeks preceding enrollment in the study

Exclusion Criteria:

* currently taking any cognitive enhancers or stimulants
* people with a history of Multiple Sclerosis, Traumatic Brain Injury, loss of consciousness lasting more than 5 minutes, seizures, dementia, or other organic brain-related disorders
* current Alcohol or Substance Abuse and/or a history of Alcohol or Substance Dependence
Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies

The purpose of this trial is to determine if patients with hematologic diseases who have a HLA 6/6 matched related donor and are not eligible for a standard myeloablative stem cell transplant will have less severe graft versus host disease (GVHD), transplant related mortality, and less graft failure when treated with a non-myeloablative T-cell depleted stem cell transplant.

Our prior experience in the lab and in clinical trials with non-myeloablative HLA-matched and mismatched transplant strategies have been remarkable for a low transplant related mortality rate, but a still formidable risk of GVHD and graft rejection. In this trial, we have incorporated a combination ex-vivo T-cell depletion strategy to prevent GVHD with vigorous in vivo depletion of host (and to a lesser extent donor) T-cells to prevent graft rejection.

Patients will receive non-myeloablative conditioning with cyclophosphamide, thymoglobulin, fludarabine, and thymic irradiation, followed by a T-cell depleted PBSC infusion. Cyclosporine will be given for GVHD prophylaxis, and tapered beginning on day 35. Data from our mouse model and previous clinical trials have demonstrated that this approach can induce mixed chimerism without GVHD, with the potential for conversion of mixed chimerism to full donor hematopoiesis following donor leukocyte infusions.

Eligibility Criteria:
Inclusion Criteria:

* Disease statue: NHL, HD, or MM that are chemorefractory or relapsed; CLL that is Rai Stage III/IV, or lymphocyte doubling time of 6 months, or stage I/II that is resistant to \> 2 chemotherapy regimens; AML or ALL in 1st or subsequent remission with poor prognostic features; CML in accelerated or blast phae; MDS with life-threatening cytopenias; patients who have had a previous autologous or allogeneic bone marrow or stem cell transplant; other hematologic disorders which allogeneic stem cell transplantation is appropriate where the risk of conventional transplantation is considered to be unacceptably high.
* Estimated disease-free survival of less than one year
* ECOG performance status of 0, 1, or 2
* HLA-genotypically or phenotypically matched (at A, B, DR loci) related donor

Exclusion Criteria:

* Patients who life expectancy is limited by diseases other than their hematologic malignancy.
* Cardiac Disease: symptomatic congestive hearth failure, or RVG, or ejection fraction of \< 45%, active angina pectoris, or uncontrolled hypertension.
* Pulmonary Disease: severe chronic obstructive lung disease, or symptomatic restrictive lung disease, or DLCO of \< 50%.
* Renal Disease: serum creatinine \> 2.0 mg/dl or creatinine clearance \< 50 ml/min.
* Hepatic Disease: serum bilirubin \> 2.0 mg/dl or alkaline phosphatase, SGOT or SGPT \> 3 times normal.
* Neurologic Disease: symptomatic leukoencephalopathy, active CNS malignancy or other neuropsychiatric abnormalities believed to preclude transplantation
* HIV or HTLV I antibody or Hepatitis B surface antigen positivity
* Uncontrolled infection
TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multi-Center Safety Surveillance Program

The TAXUS ARRIVE study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.


Eligibility Criteria:
Appropriate Patient Criteria:

* Patient is eligible to receive a Boston Scientific TAXUS Stent.

Inappropriate Patients Criteria:

* Known sensitivity to paclitaxel.
* Known allergy to stainless steel.
* Patients in whom antiplatelet and / or anticoagulant therapy is contraindicated.
* Patients judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the stent or delivery device.
* Patients with unresolved vessel thrombus at the lesion site.
* Patients with coronary artery reference vessel diameters \< 2.5 mm or \> 3.75 mm.
* Patients with lesions located in the left main coronary artery, ostial lesions, or lesions located at a bifurcation.
* Patients with diffuse disease or poor overflow distal to the identified lesions.
* Patients with tortuous vessels in the region of the obstruction or proximal to the lesion.
* Patients with a recent acute myocardial infarction where there is evidence of thrombus or poor flow.
Evaluation of Using Patient Specific Zirconium Dioxide Implant Versus Patient Specific Titanium Implant in Treatment of Chronic Condylar Dislocation

Alternate hypothesis that treatment of Tempromandibular joint dislocation with Zirconium Dioxide eminoplasty will be more efficient than using titanium onlays in terms of decreasing maximum inter incisal distance and providing better soft tissue response and post-operative patient satisfaction.


Eligibility Criteria:
Inclusion Criteria:

* Patient with recurrent dislocation with maximum inter incisal opening over 55mm
* Long-standing dislocation of the TMJ involving both fixation for more than 3 weeks and the failure of manual reduction
* Failure of conservative strategies such as orientation to self-limit jaw movement and the use of a chin-cap or bandage
* Both sexes
* Age between 18 and 48 years.
* Highly motivated patients.

Exclusion Criteria:

* Post-menopausal females with osteoporosis
* Patient with uncontrolled systemic disease
* pregnancy
* psychological disorders, drug or alcohol dependency
* Known allergies or sensitivities to dental materials, including Zirconia, Titanium or general anesthetic agents
* Inability to return for follow up visits.
* Refusal of participation from the patient
Sexuality After Reduction Mammaplasty

The aim of this study is to determine the impact of reduction mammaplasty on sexuality and depression predictors in women with macromastia.

Breast hypertrophy is a common condition among women. Reduction mammaplasty is an effective and well established procedure performed for the relief discomfort associated with breast hypertrophy. Female breasts play an important role in sexuality, thus, the main purpose of this study is to determine whether reduction mammaplasty could influence sexual function and depression predictors on women with breast hypertrophy.

Eligibility Criteria:
Inclusion Criteria:

* breast hypertrophy
* candidate to reduction mammaplasty
* healthy volunteer with normal volume breasts (control group)
* body mass index under 30Kg/m2

Exclusion Criteria:

* pregnancy, delivery or breast feeding during the last 12 months
* body mass index over 30Kg/m2
* breast cancer history
* previous breast surgery
* hard smoking
Prevalence and Clinical Spectrum of the 22q11 Deletion

The purpose of this project is to conduct population based surveillance for prenatally diagnosed congenital defects amount residents of the five counties to: improve the comprehensiveness of the Metropolitan Atlanta Congenital Defects Program (MACDP) to (1) better fulfill its objectives (2) allow assessment of the impact of prenatal diagnosis and elective termination on the birth prevalence of congenital defects in Atlanta (3) develop a registry of prenatally diagnosed defects to be used in epidemiologic and genetic studies, in evaluation prevention programs and in monitoring prenatal diagnostic technology.

Since 1967, The Centers for Disease Control and Prevention (CDC) has conducted surveillance of birth defects in metropolitan Atlanta through review of hospital delivery and newborn medical records and records from various other medical sources in the five central counties of the metropolitan area (Clayton, Cobb, DeKalk, Fulton and Gwinnett, and has been expanded to include prenatal records. The project was begun n the aftermath of thalidomide and rubella epidemics as a kind of early-warning system for new or resurgent teratogens. The voluntary participation of Atlanta hospitals was sought and obtained at the inception of the system (the original system was a joint effort of the CDC, the Georgia Institute of Mental Health and Emory University).

A case must be diagnosed by the child's sixth birthday or within six years of the date of elective termination.

Children's Healthcare is one retrospective source of medical records reviewed for discharge summaries and disease indices.

Eligibility Criteria:
Inclusion Criteria:

* birth defect diagnosed by the child's sixth birthday
* birth defect diagnosed within 6 years of the elective date of termination

Exclusion Criteria:

* those who do not meet inclusion criteria
Hypertensive Pregnant Women Monitored by Teletransmitted Self-measurements of Blood Pressure

The occurrence of arterial hypertension (AH) during pregnancy is a major cause of fetal, neonatal and maternal morbidity and mortality in western countries. It is estimated that about 10% of pregnancies are complicated by AH (80 000 women / year in France). It is therefore essential to diagnose AH with certainty in order to set-up appropriate care and follow its evolution.

The objective of this study is to show the faisability of self-measurement with teletransmission for long-term follow-up of hypertensive pregnant women (at high risk of preeclampsia) by avoiding repeated, prolonged visits or hospitalizations and to optimize the intervention of health professionals by providing them with reliable data.

A multicenter, controlled study will be conducted in women presenting with mild to moderate hypertension without preeclampsia followed throughout their pregnancy by either self-measurement with teletransmission.

Eligibility Criteria:
Inclusion Criteria:

* Pregnant women with confirmed mild to moderate AH untreated and / or under antihypertensive treatment (for gestational or chronic hypertension)
* Women without preeclampsia requiring enhanced AH surveillance
* Patient affiliated to a social security system
* Patient giving consent to participate in the study.
* Age\> 18 years

Exclusion Criteria:

* arm circumference greater than 42 cm unsuitable for self-measurement,
* women in atrial fibrillation, or frequently in arrhythmia, with secondary hypertension or severe hypertension or with cardiovascular complication.
* women having preeclampsia.
* women having an AH by "white coat effect".
* women having a move or maternity change planned during pregnancy.
* majors protected under tutorship or curatorship, or under the protection of justice.
Outcomes and Cost Consequences of Using an Internet Co-Management Module to Improve the Quality of Type 1 Diabetes Care

The researchers will conduct a 12-month randomized controlled trial comparing usual care versus chronic disease management using the Internet among patients with type 1 diabetes receiving care in the Diabetes Care Center at the University of Washington.

We will conduct a 12-month randomized controlled trial comparing usual care versus chronic disease management using the Internet among patients with type 1 diabetes on multiple daily injections with insulin glargine and rapid-acting analogs. Specifically, the objectives of the study are to:

1. Evaluate the difference in glycemic control (HbA1c) between intervention and control,
2. Evaluate the difference in resource utilization and costs of care between intervention and control, and
3. Evaluate the difference in satisfaction with care between intervention and control.

A total of 80-85 subjects will be recruited from patients receiving care in the Diabetes Care Center (DCC) at the University of Washington in Seattle. As part of a pretest-posttest experimental design, intervention-group subjects will be trained in the use of an existing diabetes disease-management module comprising six related Web sites that are accessed from home via links displayed within the University's "MyUW" Internet portal. These sites allow patients to:

1. View their entire electronic medical record including clinical reminders, the same record used by providers,
2. Upload blood glucose readings stored in a digital meter,
3. Manually enter medication, nutrition, and exercise data into an online daily diary,
4. Communicate with providers regarding treatment recommendations or other questions using a clinical e-mail service,
5. Obtain additional information from a traditional education site whose content and links were sanctioned by the Medical Director of the DCC, and
6. Employ a second education site to collaboratively generate action plans intended to enhance self-efficacy.

In addition to login and password protection, access to confidential information from home requires the use of secondary authentication (SecureID). All clinical and other data can be viewed by patients and providers in online trended displays that will be used by a nurse practitioner to review cases no less than weekly. As the control group, subjects receiving usual care will not have access to the diabetes module and related case-management services being evaluated.

The primary clinical outcome for the study is the between group differences in glycemic control using HbA1c as the metric. A co-primary outcome is all direct medical care utilization. Satisfaction with diabetes care, employing both a quantitative survey (Patient Assessment of Chronic Illness Care) and semi-structured interviews performed on a 20% purposive sub-sample of intervention patients, is a secondary outcome measure.

Eligibility Criteria:
Inclusion Criteria:

* Computer and Internet access at home
* Receiving care at the University of Washington Diabetes Care Center

Exclusion Criteria:

* Non-English speaking
Study of Effects of Sutures on Results of Palate Surgery for Obstructive Sleep Apnea

In this study we will examine whether suture repair of the palate, or roof of mouth, has any effect on results of palate surgery performed for treatment of obstructive sleep apnea.

Uvulopalatopharyngoplasty, or UPPP, is the most common surgical procedure performed for the treatment of obstructive sleep apnea. The procedure involves removal of redundant tissue from the lower palate (roof of mouth), including the uvula, and then suturing the cut edges of the remaining tissue together. However it is frequently noted by surgeons that sutures placed in the roof of the mouth do not stay intact. Also, in standard tonsillectomy, which involves removal of the tonsils and thus creation of a wound near the palate, no suturing is used, which does not seem to affect how the area heals. Previous studies have shown no significant differences in complication rates, post-operative pain, or symptom outcomes in patients undergoing tonsillectomy either with or without suture repair of the tonsillectomy wound. In this study we will examine whether suture repair following UPPP has any effect on post-operative pain, healing, or treatment success in terms of symptom resolution or post-operative sleep study results.

Eligibility Criteria:
Inclusion Criteria:

* sleep-study documented obstructive sleep apnea
* sleep apnea refractory to non-surgical treatments including continuous positive airway pressure (CPAP)
* age \> 21

Exclusion Criteria:

* previous palate surgery
The Copenhagen Triage Algorithm

Crowding in the emergency department (ED) is a well documented problem putting patients at risk of adverse outcomes. To combat this, most ED's use some form of triage. In the last two decades systematic triage or process triage has become the norm in most countries but this approach is supported by limited evidence. Our aim is to develop a faster triage model of only a few vital parameters, based on a data from a large cohort of unselected ED patients and evaluate if such a model combined with a clinical assessment by the ED nurse is inferior to existing triage models in a prospective cluster-randomized trial


Eligibility Criteria:
Inclusion Criteria:

* Patients presenting acutely to the Acute ward/Emergency department in two hospitals in the Capital of Denmark

Exclusion Criteria:

* Patients presenting in Pediatric, Gynecological or Obstetric units
The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia

The spleen in Sickle Cell Anemia and Sickle Cell Thalassemia is usually enlarged in the first years of life but the immune protection provided is considered insufficient. In homozygous Sickle cell patients the spleen usually developed recurrent infarcts and after the first decade of age become fibrotic. Acute splenic sequestration is also frequent in those patients and this is considered as an indication for splenectomy.

In comparison in Sickle cell thalassemia patients, hypersplenism is more frequent.

The purpose of this study is to compare the clinical and laboratory issues related to the spleen in two groups of Sickle cell patients.

Clinical and laboratory characteristics related to the spleen in SCA patients will be studied.

Two groups of patient will be compared, a group of Sickle cell patients (Homozygous) and a second group of patients with Sickle cell beta thalassemia.

In those patients that splenectomy was performed the incidence of infections will be recorded besides the indications for splenectomy and the incidence of thrombotic events or thrombocytosis.

Eligibility Criteria:
Inclusion Criteria:

* All the patients followed up at the Pediatric Hematology Unit

Exclusion Criteria:

* Patients lost from follow up of with insufficient data
Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms

Safety and Efficacy of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) ophthalmic compound to improve uncorrected near vision in healthy presbyopic patients one hour after instillation.

To determine the safety and efficacy of a novel pharmacological compound of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) to improve uncorrected near vision in healthy presbyopic patients one hour after binocular instillation.

Eligibility Criteria:
Inclusion Criteria:

* Healthy
* Presbyopic
* 40 - 60 years

Exclusion Criteria:

* Diabetics
* Previous eye surgery
* Previous eye disease
* \> 0.50 myopia
* \> 1.5 hyperopia or astigmatism
Exercise Effects in Native American Adolscents

This longitudinal study will investigate effects of exercise participation in Southwest Native American adolescents, ages 11-17, from the Gila River Indian Community. Vital signs, physical activity participation adherence, physical performance measures, and psychological/social measures will be assessed. Participants will attend one educational presentation for the initial session, explaining the benefits of physical exercise and expectations throughout the program. Baseline measurements for strength, flexibility, and cardiovascular fitness will be taken as well as height, weight and blood pressure. Based on individual performance measures, each participant will be provided a personalized exercise program to complete 3-4 times/week for the duration for the duration of the study. Participants will also be provided an exercise journal to track their adherence to their exercise program each week. At the end of the session parents and adolescents separately will be asked to complete a written survey assessing physical, emotional, social, and school function. Physical performance measures will be taken every other week from the initial education and data collection session through 6 weeks.


Eligibility Criteria:
Inclusion Criteria:

* Active members of the Gila River Indian Community (GRIC) with Native American ancestry
* Ages 11-17

Exclusion Criteria:

* Not active members of the GRIC or no Native American ancestry
* Age \<11 or \>17